Objective: ApoAV, a newly discovered apoprotein, affects plasma triglyceride level. To determine how this occurs, we studied triglyceride-rich lipoprotein (TRL) metabolism in mice deficient in apoAV.
Methods And Results: No significant difference in triglyceride production rate was found between apoa5(-/-) mice and controls. The presence or absence of apoAV affected TRL catabolism. After the injection of 14C-palmitate and 3H-cholesterol labeled chylomicrons and (125)I-labeled chylomicron remnants, the disappearance of 14C, 3H, and (125)I was significantly slower in apoa5(-/-) mice relative to controls. This was because of diminished lipolysis of TRL and the reduced rate of uptake of their remnants in apoa5(-/-) mice. Observed elevated cholesterol level was caused by increased high-density lipoprotein (HDL) cholesterol in apoa5(-/-) mice. VLDL from apoa5(-/-) mice were poor substrate for lipoprotein lipase, and did not bind to the low-density lipoprotein (LDL) receptor as well as normal very-low-density lipoprotein (VLDL). LDL receptor levels were slightly elevated in apoa5(-/-) mice consistent with lower remnant uptake rates. These alterations may be the result of the lower apoE-to-apoC ratio found in VLDL isolated from apoa5(-/-) mice.
Conclusions: These results support the hypothesis that the absence of apoAV slows lipolysis of TRL and the removal of their remnants by regulating their apoproteins content after secretion.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1161/01.ATV.0000186189.26141.12 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Article Synopsis
- Abdominal aortic aneurysm (AAA) is a serious vascular disease that currently lacks effective treatments, prompting research into its causative factors.
- This study used genetic, proteomic, and metabolomic approaches along with mouse models to show that high levels of triglycerides (TG) contribute significantly to the development and rupture of AAA.
- The findings highlight that managing triglyceride-rich lipoproteins could be crucial for treating AAA and suggest that targeting TG pathways may inhibit AAA progression.
APOA5 deficiency causes hypertriglyceridemia by reducing amounts of lipoprotein lipase in capillaries.
J Lipid Res
July 2024
Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA, USA; Department of Human Genetics, David Geffen School of Medicine, University of California, Los Angeles, CA, USA. Electronic address:
Apolipoprotein AV (APOA5) deficiency causes hypertriglyceridemia in mice and humans. For years, the cause remained a mystery, but the mechanisms have now come into focus. Here, we review progress in defining APOA5's function in plasma triglyceride metabolism.
View Article and Find Full Text PDFAPOA5 alleviates reactive oxygen species to promote oxaliplatin resistance in PIK3CA-mutated colorectal cancer.
Aging (Albany NY)
June 2024
Department of Otolaryngology-Head and Neck Surgery, Shandong Provincial ENT Hospital, Cheeloo College of Medicine, Shandong University, Jinan 250023, China.
Although platinum-based chemotherapy is the frontline regimen for colorectal cancer (CRC), drug resistance remains a major challenge affecting its therapeutic efficiency. However, there is limited research on the correlation between chemotherapy resistance and lipid metabolism, including PIK3CA mutant tumors. In this present study, we found that PIK3CA-E545K mutation attenuated cell apoptosis and increased the cell viability of CRC with L-OHP treatment and .
View Article and Find Full Text PDFCarboxyl-terminal sequences in APOA5 are important for suppressing ANGPTL3/8 activity.
Proc Natl Acad Sci U S A
April 2024
Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 462585.
Article Synopsis
- Apolipoprotein AV (APOA5) helps lower fat levels (triglycerides) in the blood by stopping another protein complex (ANGPTL3/8) from interfering with lipoprotein lipase (LPL), which breaks down fats.
- Researchers found that a mutation in APOA5 leads to higher triglyceride levels, meaning certain parts of the protein are needed to perform its job well.
- Experiments with mice showed that the normal version of APOA5 worked to reduce triglyceride levels, while a modified version without important parts didn’t, highlighting those parts' key role in keeping fat levels in check.
Depletion of ApoA5 aggravates spontaneous and diet-induced nonalcoholic fatty liver disease by reducing hepatic NR1D1 in hamsters.
Theranostics
March 2024
Institute of Cardiovascular Sciences, State Key Laboratory of Vascular Homeostasis and Remodeling, School of Basic Medical Sciences, Peking University, Beijing, China.
ApoA5 mainly synthesized and secreted by liver is a key modulator of lipoprotein lipase (LPL) activity and triglyceride-rich lipoproteins (TRLs). Although the role of ApoA5 in extrahepatic triglyceride (TG) metabolism in circulation has been well documented, the relationship between ApoA5 and nonalcoholic fatty liver disease (NAFLD) remains incompletely understood and the underlying molecular mechanism still needs to be elucidated. We used CRISPR/Cas9 gene editing to delete Apoa5 gene from Syrian golden hamster, a small rodent model replicating human metabolic features.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!